Treatment resistant Lyme arthritis caused by Borrelia garinii

F-X Limbach, B Jaulhac, X Puechal, H Monteil, J-L Kuntz, Y Piemont, J Sibilia

Abstract
Lyme arthritis is caused in Europe by three main pathogenic species of Borrelia burgdorferi sensu lato: Borrelia burgdorferi sensu stricto, Borrelia garinii, and Borrelia afzelii. Because few synovial samples have yet been analysed by species-specific DNA amplification methods, further studies are needed to define the spectra of clinical manifestations associated with these different species. Two cases of treatment resistant Lyme arthritis are reported here, in which DNA amplification of the flagellin gene followed by dot-blot hybridisation in the synovial fluid identified B garinii as the causative agent. Clinical and biological data did not differ from the usual descriptions of Lyme arthritis, but as the recently reported molecular mimicry between OspA and hLFA1 is not applicable to B garinii, the pathogenesis of the present cases remains unclear. Future studies should aim at assessing the role of B garinii in European Lyme arthritis and its possible pathogenic and therapeutic consequences. (Ann Rheum Dis 2001;60:284–286)

Recently, four European groups and our own identified the Borrelia species involved in some forms of Lyme arthritis. A variety of identification techniques were used, including DNA sequencing of OspA, OspA species-specific primers, and reverse line blotting of synovial fluid. Discordant results were obtained, particularly concerning the role of B garinii, while the clinical presentation and outcome of patients were not described in detail. Furthermore, because only a few synovial fluid samples were analysed by species-specific DNA amplification methods, studies are still needed to determine which spectrum of clinical manifestations is associated with B garinii. In the present work we describe two patients with treatment resistant Lyme arthritis, in whom DNA amplification and dot-blot hybridisation identified B garinii as the causative species.

Case reports

PATIENT 1
Patient 1, a 41 year old woman, presented in December 1993 with a history of monarthritis of the right knee. This had developed in August 1991, a few months after the disappearance of a concentric erythematous eruption on the calf. She could not recall having been bitten by a tick during her frequent forest walks near Paris (France). The right knee swelling had been treated several times between August 1991 and January 1993 with corticosteroid infiltrations, but this treatment had never been effective for more than six months. The patient had no history of psoriasis, low back pain, or genital infection.

On examination at the rheumatology department the right knee was found to be swollen, though with minimal pain. The synovial fluid contained 28 × 10^3 leucocytes/l (64% polymorphonuclear cells and 36% lymphocytes), while a synovial biopsy specimen showed a dense inflammatory infiltrate of lymphocytes and plasmocytes. Tests for antinuclear antibodies and rheumatoid factor were negative and the patient’s haplotype was HLA-B18/40 and DRB1*0403/*0404. Radiographs of the right knee showed demineralisation without any erosion. Chlamydia trachomatis serology was negative. A serological enzyme linked immunosorbent assay (ELISA) test for Lyme disease was strongly positive with values of 4.2 for IgG (>1.1 positive) and negative for IgM, which were confirmed by western blot analyses. Because only small amounts of synovial fluid were available, DNA amplification specific for B burgdorferi sensu lato was not interpretable. The patient was treated with doxycycline.

Rheumatology
Department, Hôpitaux Universitaires de Strasbourg, France
F-X Limbach
J-L Kuntz
J Sibilia

Bacteriology
Department, Hôpitaux Universitaires et Faculté de Médecine de Strasbourg, France
B Jaulhac
H Monteil
Y Piemont

Rheumatology
Department, Hôpital Universitaire Cochin, Paris, France
X Puechal

Correspondence to:
Dr J Sibilia, Service de Rhumatologie, CHU Strasbourg Hautepierre, 1 Avenue Molaire, 67098 Strasbourg
jean.sibilia@wanadoo.fr

Accepted 28 June 2000

www.annrheumdis.com
Lyme arthritis caused by Borrelia garinii

In July 1994 the patient had her first relapse since antibiotic treatment. Puncture of the knee yielded 10 ml of fluid containing 10.4 x 10^9 leucocytes/l (21% polymorphonuclear cells and 68% lymphocytes), while serological ELISA tests gave a value of 2.5 for IgG and were negative for IgM. The patient was treated parenterally with ceftriaxone (2 g/day) for three weeks. Owing to persistent swelling, tramcinolone hexacetonide (40 mg) was injected into the knee, with successful results.

When painful swelling recurred in January 1995, knee puncture disclosed a synovial fluid containing 7.8 x 10^9 leucocytes/l (45% polymorphonuclear cells and 20% lymphocytes). In this last fluid, DNA amplification using a polymerase chain reaction (PCR) specific for B burgdorferi sensu lato was positive. The patient was successfully treated by an intra-articular injection of 10 ml of 1% osmic acid.

In October 1995 symptoms recurred, and knee puncture yielded 25 ml of inflammatory synovial fluid. A third course of antibiotic treatment was given, ceftriaxone (2 g/day) parenterally for three weeks. There was further swelling in 1996 requiring the removal of 40 ml of synovial fluid (6.2 x 10^9 leucocytes/l, 90% of which were lymphocytes), and in 1998 still a little swelling of the right knee persisted.

PATIENT 2

Patient 2, a 27 year old man living in the East of France, was referred in February 1998 for arthritis of the left knee. An effusion of the left knee joint, which had developed five months previously, had been treated initially with non-steroidal anti-inflammatory drugs and, because of a lack of efficacy, with an intra-articular cortivazol injection in November 1997. After a transient improvement, swelling of the left knee had recurred 15 days later. As this patient lives in an endemic area, was frequently bitten by ticks, and had a possible previous history of erythema migrans in September 1996, treatment with amoxicillin (4 g/day orally) was given in December 1997 for three weeks but without effect.

Physical examination showed a marked swelling of the left knee, which was moderately painful. Radiographs of the knees, hands, and sacroiliac joints were normal, and tests for antinuclear antibodies, rheumatoid factor, and Chlamydia trachomatis were negative. The patient's haplotype was HLA-B7/62 and DBR1*0101/*11. Blood tests showed an increase in the acute phase reactants (erythrocyte sedimentation rate 86 mm/1st h, C reactive protein 80 mg/l), with a normal white blood cell count. Lyme serology was positive by ELISA with values of 1450 U for IgG (>9 U positive) and 41 U for IgM (>10 U positive), which were confirmed by western blot analyses. The synovial fluid contained 20 x 10^9 leucocytes/l (80% polymorphonuclear cells and 20% lymphocytes) and DNA amplification using a PCR specific for B burgdorferi sensu lato was positive in this sample. The patient was treated for three weeks with intravenous ceftriaxone (2 g/day) and was completely cured, with no recurrence after an 18 months' follow up.

Methods

Synovial fluid samples were obtained from each patient by needle puncture. PCR amplification of a central part of the flagellin gene, using as primers two oligonucleotides specific for all B burgdorferi sensu lato species, was performed as previously described with both synovial fluids and gave positive results. To avoid DNA contamination of samples, precautions previously described were taken. A species-specific dot-blot hybridisation assay was then performed on the PCR products. Oligonucleotide probes specific for the following B burgdorferi sensu lato species were used: B burgdorferi sensu stricto, B garinii, B afzelii, B japonica, B andersonii, B valaisiana, and B bissetti. Synovial samples from the two patients hybridised only with the B garinii probe and there was no evidence of mixed infection.

Discussion

This is the first description of Lyme arthritis caused by B garinii, which was treatment resistant in the first case and amoxicillin resistant in the second patient. After intra-articular corticosteroids. Although a diagnosis of Lyme arthritis is obvious for the second patient, the history of the first patient is more complicated. However, this diagnosis was retained based on the following data: possible erythema migrans, recurrent monarthritis with a positive serology for B burgdorferi, positive PCR, the specificity of which has previously been shown to be absolute for B burgdorferi when precautions are taken to avoid cross contamination between samples. No other diagnosis was made after seven years' follow up. It is noteworthy that the clinical manifestations and biological data of these patients did not differ from the usual descriptions of Lyme arthritis. Thus both had a possible history of tick bites and erythema migrans, knee arthritis with marked swelling but minimal pain, and concordant serological data. This uniform clinical presentation of Lyme arthritis, whatever the species involved, differs from the recent reports of patients presenting with erythema migrans, in whom different symptoms were observed according to whether the causative agent was B burgdorferi sensu stricto or B afzelii. In our two patients, as previously reported in other cases of Lyme arthritis, local corticosteroid treatment resulted in a temporary improvement, but might have been implicated in the resistance to amoxicillin in the second patient. The most striking clinical feature of these two patients was the persistent arthritis for years after several courses of antibiotics, including ceftriaxone twice in the first case and seven weeks after amoxicillin in the second patient. Because B garinii DNA was still detected in synovial fluid two years after the onset of disease despite two courses of antibiotics in the first patient, the chronic persistence of B garinii is likely. However, even if we and others have previously demonstrated the persistence of
In summary, B. garinii can be implicated in European Lyme arthritis and gives a clinical presentation similar to that of B. burgdorferi sensu stricto. Moreover, Lyme arthritis due to B. garinii may be associated in susceptible hosts with amoxicillin resistance or treatment resistance, as in these two patients. The recently described molecular mimicry between OspA and hLFA1 may not be applicable to these patients and future studies should aim at assessing further the role of B. garinii in European Lyme arthritis and its possible pathogenic and therapeutic consequences.

The authors are grateful to SE Malawista for helpful discussion and criticism of the manuscript, and to D Herb and C Barthel for excellent technical assistance.

Part of this work was supported by the Programme Hospitalier de Recherche Clinique 1995.

Treatment resistant Lyme arthritis caused by *Borrelia garinii*

F-X Limbach, B Jaulhac, X Puechal, H Monteil, J-L Kuntz, Y Piemont and J Sibilia

*Ann Rheum Dis* 2001 60: 284-286
doi: 10.1136/ard.60.3.284

Updated information and services can be found at:
http://ard.bmj.com/content/60/3/284

These include:

**References**

This article cites 14 articles, 5 of which you can access for free at:
http://ard.bmj.com/content/60/3/284#BIBL

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**

Articles on similar topics can be found in the following collections

- *Degenerative joint disease* (4641)
- *Musculoskeletal syndromes* (4951)
- *Genetics* (968)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/